Becker's Healthcare January 16, 2025
Recent changes to the federal 340B drug discount program have led to cost increases for low-income patients and the community health clinics that serve them, The New York Times reported Jan. 16.
The program, which provides discounts on prescription medications for clinics treating low-income patients, has been affected by the Inflation Reduction Act and other federal pricing measures. In response, pharmaceutical companies lowered the prices of certain drugs in 2024 to avoid penalties for price increases.
However, the price reductions have inadvertently raised costs for clinics, which no longer receive the same discounts. For example, drugs such as Victoza, a diabetes...